Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reference product Clear all
Terminated Phase 2Phase 3 Interventional Results available

Sedation With Dexmedetomidine During Cardiac Catheterization

NCT01072643
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Dexmedetomidine
Drug
Lead sponsor
Aruna Nathan
Other
Eligibility
8 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 30, 2026, 10:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol

NCT04746989
View directory record Official record
Conditions
Gout
Interventions
Probenecid, Allopurinol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
294,878 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Recruiting Phase 3 Interventional

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT05696613
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
SNP-ACTH (1-39) Gel, Rituximab
Drug
Lead sponsor
Cerium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Los Angeles, California • San Dimas, California • Tarzana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants

NCT05968482
View directory record Official record
Conditions
Healthy
Interventions
Diclofenac Sodium Gel
Drug
Lead sponsor
Amzell
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 30, 2026, 10:37 PM EDT
Not listed Phase 3 Interventional

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

NCT02249663
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 3 Interventional

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

NCT06154304
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation), Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1, Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2, Placebo
Drug
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 30, 2026, 10:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Infant Formula and Toddler Drink Feeding Intervention

NCT04495738
View directory record Official record
Conditions
Respiratory Infections in Children
Interventions
Control Infant Formula, Control Toddler Drink, Experimental Infant Formula, Experimental Toddler Drink, Supplemental Formula for HM Group, Toddler Drink for HM group
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 14 Days
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
27
States / cities
Dothan, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions

NCT01157169
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

NCT03287791
View directory record Official record
Conditions
Rosacea
Interventions
Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam, Cleanser, Sunscreen, Towel, Moisturizing Lotion
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Encino, California • La Mesa, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 30, 2026, 10:37 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Icotrokinra, Placebo, Active reference comparator
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Jonesboro, Arkansas • DeBary, Florida • Plantation, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

NCT02770365
View directory record Official record
Conditions
Atrophy
Interventions
estrace cream (Perrigo), estrace cream (Reference), Placebo cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of the Level of Dietary Protein on Infant Growth

NCT00716105
View directory record Official record
Conditions
Infant Nutrition
Interventions
Standard infant formula, Infant formula with different level of proteins
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
3 Months to 12 Months
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
2
States / cities
Iowa City, Iowa • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

NCT00944346
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Oct 30, 2026, 10:37 PM EDT
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers

NCT05041166
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Hyperpolarized [13C] Pyruvate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Terminated Phase 3 Interventional Results available

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

NCT02417129
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Rituximab, BI 695500
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Muscle Shoals, Alabama • Bakersfield, California • Burbank, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 30, 2026, 10:37 PM EDT
Recruiting Phase 3 Interventional

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

NCT03179605
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Madera, California • Santa Ana, California • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

NCT02823171
View directory record Official record
Conditions
Healthy
Interventions
Treatment A: 400 mg Pacritinib P3CT, Treatment B: 400 mg of pacritinib FMI
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 30, 2026, 10:37 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

NCT07285148
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
Interventions
ANS014004 + PLB1004, ANS014004 + Osimertinib
Drug
Lead sponsor
Beijing Pearl Biotechnology Limited Liability Company
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions

NCT00840411
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

NCT01517399
View directory record Official record
Conditions
Solid Tumors
Interventions
tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam
Drug · Dietary Supplement
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

NCT01289509
View directory record Official record
Conditions
Idiopathic Thrombocytopenia Purpura
Interventions
E5501, Drug: E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

NCT03528577
View directory record Official record
Conditions
Asthma
Interventions
Zero-dose, 90 mcg of PROAIR® HFA, 180 mcg of 90 mcg of PROAIR® HFA, 90 mcg of albuterol sulfate inhalation aerosol
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Miami Lakes, Florida • Bethesda, Maryland • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration

NCT03324061
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Fulvestrant for Injectable Suspension, Faslodex (Reference)
Drug
Lead sponsor
Eagle Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
12
States / cities
Long Beach, California • DeLand, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 30, 2026, 10:37 PM EDT